Abstract
CD73, also known as ecto-5’-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.
Keywords: CD73, ecto-5'-nucleotidase, cancer, immunity, inflammation, disease.
Current Medicinal Chemistry
Title:Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Volume: 25 Issue: 19
Author(s): Jiayin Yang, Xiaohong Liao, Jerry Yu and Ping Zhou*
Affiliation:
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032,China
Keywords: CD73, ecto-5'-nucleotidase, cancer, immunity, inflammation, disease.
Abstract: CD73, also known as ecto-5’-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.
Export Options
About this article
Cite this article as:
Yang Jiayin, Liao Xiaohong, Yu Jerry and Zhou Ping *, Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target, Current Medicinal Chemistry 2018; 25 (19) . https://dx.doi.org/10.2174/0929867325666180117101114
DOI https://dx.doi.org/10.2174/0929867325666180117101114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research The Inflammatory Response in Cardiac Surgery: An Overview of the Pathophysiology and Clinical Implications
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress in the ICU
Current Nutrition & Food Science Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets Pharmacological Treatment of Hypoxic-Ischemic Reperfusion Injury of the Newborn Brain in the Clinical Setting: What are the Possibilities in the Near Future?
Current Pediatric Reviews Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Estrogen Regulation of MicroRNA Expression
Current Genomics Natural Products and Cancer Stem Cells
Current Pharmaceutical Design NMNAT Expression and its Relation to NAD Metabolism
Current Medicinal Chemistry Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Vasoprotective Actions of the Atrial Natriuretic Peptide
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Δ<sup>α,β</sup>-Butenolides [Furan-2(5<i>H</i>)-ones]: Ring Construction Approaches and Biological Aspects - A Mini-Review
Mini-Reviews in Organic Chemistry